Teva Pharmaceutical Industries and Active Biotech have reported positive data from three-year Phase III study of oral laquinimod conducted in relapsing-remitting multiple sclerosis (RRMS) patients.

Early treatment with laquinimod demonstrated a significant reduction in risk of disability progression, compared to delayed treatment, in the open-label study.

Teva Pharmaceutical Industries chief scientific officer and global R&D president Dr Michael Hayden said the laquinimod study results suggest benefits of early treatment for RRMS and the potential to delay disability.

"Early treatment with laquinimod demonstrated a significant reduction in risk of disability progression, compared to delayed treatment, in the open-label study."

"The development of laquinimod’s clinical profile has been full of exciting revelations about the compound’s unique mechanism of action, and we were dually encouraged by the preclinical data which demonstrated a potential direct effect on neuroregenerative processes," Hayden said.

The effectiveness of laquinimod in patients who received 36 months (early-start) against those who received 24 months of laquinimod treatment (delayed-start) was compared in the double-blind study.

97% of the 864 RRMS patients took part in the open-label extension and 87% completed one year of the open-label phase.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Laquinimod also demonstrated a favourable safety and tolerability profile in RRMS patients without any new safety concerns.

Potential restorative and anti-inflammatory properties of laquinimod were also established in a preclinical study in animal models.